Table 1.
Demographic and clinical data of obese patients and healthy controls of the included studies.
| Author, Country | Study Design | Type of Pathology | BDNF Measurement | Cases (n) | Controls (n) | BDNF (Ng/ML) Cases Mean | BDNF (ng/mL) Controls Mean | BDNF (ng/mL) Weighted Average | Age (Years) Cases | Age (Years) Controls | Age (Years) Mean | Males (%) | BMI (kg/m2) Cases | BMI (kg/m2) Controls | BMI (kg/m2) Mean | WC (cm) Cases | WC (cm) Controls | WC (cm) Mean |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lee I-Te 2016, Taiwan [32] | Prospective | Obesity and MetS | Serum (ELISA) | 36 | 25 | 40.40 | 43.00 | 41.47 | 44 | 39 | 41.95 | 100.0 | 33.5 | 22.5 | 29.0 | 109.1 | 81.9 | 98 |
| Slusher AL 2015, United States [30] | Case-control/Prospective | Obesity | Plasma (ELISA) | 11 | 11 | 1.72 | 0.98 | 1.35 | 22.91 | 23.27 | 23.09 | 40.9 | 35.72 | 21.89 | 28.8 | 99.32 | 71.36 | 85.3 |
| Hinderberger P 2016, Germany [31] | Case-control | Obesity | Serum (ELISA) | 24 | 14 | 28.10 | 27.10 | 27.73 | 36.9 | 36.1 | 36.61 | 26.3 | 40.7 | 22.5 | 34.0 | ND | ND | ND |
| Gajewska E 2014, Poland [33] | Case-control | Obesity | Serum (ELISA) | 15 | 11 | 23.89 | 23.83 | 23.86 | ≤65 | ≤65 | ≤65 | 0 | >40 | ND | ND | ND | ND | ND |
| 39 | 25 | 24.11 | 23.22 | 23.76 | >66 | >66 | >66 | 0 | >40 | ND | ND | ND | ND | ND | ||||
| 12 | 7 | 23.72 | 22.95 | 23.44 | ≤65 | ≤65 | ≤65 | 100 | >40 | ND | ND | ND | ND | ND | ||||
| 14 | 21 | 24.74 | 23.94 | 23.99 | >66 | >66 | >66 | 100 | >40 | ND | ND | ND | ND | ND | ||||
| Han JC 2010, United States [34] | Cross-sectional | Obesity | Serum (ELISA) | 13 | 13 | 17.60 | 14.20 | 15.90 | 12.3 | 12.4 | 12.35 | 92 | 33.1 | 17.2 | 25.2 | ND | ND | ND |
| Corripio R 2012, Spain [35] | Prospective | Obesity | Plasma (ELISA) | 73 | 47 | 57.70 | 78.50 | 65.85 | 8.03 | 7.74 | 7.92 | 55.8 | 26.5 | 16.2 | 22.5 | 81.3 | 57.5 | 72.0 |
| Lee I-Te 2012, Taiwan [36] | Case-control | Obesity and MetS | Serum (ELISA) | 34 | 24 | 40.90 | 43.20 | 41.85 | 41 | 39 | 40.17 | 100 | 33.9 | 22.5 | 29.2 | 109.3 | 82.2 | 98.1 |
| Lee SS 2014, Korea [37] | Prospective | Obesity | Serum (ELISA) | 8 | 11 | 8.00 | 21.20 | 15.64 | 16.3 | 16.4 | 16.36 | 65 | 27.47 | 22.35 | 24.5 | ND | ND | ND |
| Levinger I 2007, Australia [38] | Prospective | Obesity and MetS | Plasma (ELISA) | 14 | 10 | 1.03 | 0.70 | 0.89 | 51.9 | 48.9 | 50.65 | 54 | 30.3 | 23.8 | 27.6 | 99.4 | 81 | 91.7 |
| Chun-Jung Huang 2014, United States [39] | Case-control | Obesity | Plasma (ELISA) | 14 | 17 | 0.28 | 0.20 | 0.24 | 22.64 | 22.94 | 22.80 | 35 | 38.18 | 21.21 | 28.9 | 111.46 | 68.74 | 88.0 |
WC: waist circumference; BMI: body mass index; ND: not declared.